By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Diatos S.A. 

Paris BioPark
3-5 Impasse Reille
Paris    75014  France
Phone: 33-1-53-80-93-40 Fax:


Drug Delivery

Company News
CELLECTIS SA Acquires Diatos S.A.'s Vectocell(R) Technology to Accelerate Therapeutic Development Programs 10/12/2009 2:44:48 PM
Drais Pharmaceuticals and Diatos S.A. Partner to Develop and Commercialize DTS-108 for Treatment of Cancer 12/22/2008 10:16:28 AM
Diatos S.A. Pre-Clinical Results Published in Clinical Cancer Research 4/1/2008 1:32:05 PM
Diatos S.A. Announces Successful Completion of Phase I Trial for DTS-201 10/22/2007 1:30:54 PM
Diatos S.A. Announces Start of the Preclinical Toxicology Program of DTS-108, a Second Generation Irinotecan 10/17/2007 1:20:38 PM
Diatos S.A. Completes a Series D €9.4 Million Private Financing Round 7/3/2007 12:07:49 PM
Diatos S.A. Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program 6/4/2007 12:25:20 PM
Diatos S.A. Strengthens Management Team With The Appointment Of New Chief Medical Officer And New Chief Sales & Marketing Officer 10/9/2006 11:43:22 AM
The Day In Review: Pfizer Inc. (PFE) Anti-Smoking Drug Chantix Gets Approved 5/11/2006 6:26:32 PM
Diatos S.A. Announces Acquisition Of Specialty Cancer Product DaunoXome(R) From Gilead Sciences (Foster City, CA) (GILD) 5/11/2006 10:36:20 AM